MEDICINA
Departamento
Javier
Crespo García
Publicaciones en las que colabora con Javier Crespo García (18)
2022
-
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
JHEP Reports, Vol. 4, Núm. 5
-
Consensus document of the Spanish Society of Digestives Diseases and the Spanish Society of Thrombosis and Haemostasis on massive nonvariceal gastrointestinal bleeding and direct-acting oral anticoagulants
Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 7, pp. 375-389
2021
-
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
2020
-
Cross-sectional association between non-soy legume consumption, serum uric acid and hyperuricemia: the PREDIMED-Plus study
European Journal of Nutrition, Vol. 59, Núm. 5, pp. 2195-2206
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Cohort profile: Design and methods of the PREDIMED-Plus randomized trial
International Journal of Epidemiology, Vol. 48, Núm. 2, pp. 387-388o
2018
-
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349
-
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349] (S0210570518300037) (10.1016/j.gastrohep.2017.12.003))
Gastroenterologia y Hepatologia
-
Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry
Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1495-1502
-
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C
Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948
-
Mediterranean diet and quality of life: Baseline cross-sectional analysis of the PREDIMED-PLUS trial
PLoS ONE, Vol. 13, Núm. 6
-
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity
Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270
2017
-
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Hepatology, Vol. 65, Núm. 6, pp. 1810-1822
2004
-
Serum immunological profile in patients with chronic autoimmune cholestasis
American Journal of Gastroenterology, Vol. 99, Núm. 11, pp. 2150-2157
2003
-
Comparative study of the efficacy of an induction dose of interferon-α2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C
Journal of Viral Hepatitis, Vol. 10, Núm. 6, pp. 437-445